Company news
China Resources Double-crane Pharmaceutical Co., Ltd. Class A (SSE:600062) news
China Resources Double-crane Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Dec 27, 2025: Announcement on Daily Related Party Transactions
View China Resources Double-crane Pharmaceutical Co., Ltd. Class A →
Press releases — page 2
Announcement on Daily Related Party Transactions
December 26, 2025
Announcement on Notice to Creditors on Repurchasing and Canceling Some Restricted Stocks to Reduce Registered Capital
December 25, 2025
Announcement on Obtaining Approval Notice for Drug Clinical Trials for DC6001 Tablets by Wholly-owned Subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.
December 23, 2025
Notice on Convening the 3rd Extraordinary General Meeting in 2025
December 9, 2025
Announcement on the Inclusion of the Company’s Drug in the National Medical Insurance Catalog
December 8, 2025
Announcement on Wholly-owned Sub-subsidiary Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Passing GMP Compliance Inspection
December 5, 2025
Announcement on Canceling the Board of Supervisors, Amending the Articles of Association and Fully Amending Basic Management Systems
December 3, 2025
Announcement on Holding Subsidiary Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd. Receiving the Drug Supplemental Application Approval for Pioglitazone Hydrochloride Dispersible Tablets
December 1, 2025
Announcement on Wholly-Owned Subsidiary China Resources Saike Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Bisoprolol and Amlodipine Tablets
November 25, 2025
Announcement on Lifting Sales Restrictions and Circulation of Restricted Stocks in 2nd Lifting Period of Reserved Granted Portion under Restricted Stock Incentive Plan of 2021
November 24, 2025
华润双鹤关于控股子公司湖南省湘中制药有限公司奥卡西平片获得药品注册证书的公告
November 18, 2025
Announcement on the Passage of GMP Compliance Inspection by the Company's Holding Subsidiary, Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd.
November 13, 2025
Announcement on Progress in Establishment of Double-Crane Industry Fund and Related Party Transactions
October 29, 2025
Announcement on Progress in Participating in the Establishment of Double-Crane Pharmaceutical Industry Investment Fund Phase II and Related Party Transactions
October 28, 2025
Announcement on Resolutions of the 14th Meeting of the 10th Board of Directors
October 24, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
October 21, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 20, 2025
Announcement on Wholly-owned Subsidiary China Resources Double-Crane Limin Pharmaceutical (Jinan) Co., Ltd. Obtaining the Drug Registration Certificate for Bosentan Dispersible Tablets
September 29, 2025
Announcement on Wholly-Owned Subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Tirofiban Hydrochloride and Sodium Chloride Injection
September 16, 2025
Announcement on the Wholly-Owned Subsidiary Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. Receiving the Approval Notice for the Supplemental Drug Application of Peritoneal Dialysis Solution (Lactic Acid) Series
September 11, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
September 9, 2025
Announcement on Resignation of Senior Management Member
September 5, 2025
Announcement on Holding Subsidiary Second Pharma Co., Ltd. Passing GMP Compliance Inspection
September 2, 2025
Announcement on the Receipt of the Drug Supplement Approval Notice for Potassium Chloride Injection by Wholly-Owned Subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd.
August 31, 2025
Announcement on Obtaining Drug Registration Certificate for Some Products by Wholly-owned Subsidiary
August 27, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
August 22, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 20, 2025
Announcement on Establishment of Double-Crane Industry Fund and Related Party Transactions
August 12, 2025
Announcement on the Wholly-Owned Subsidiary Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. Receiving the Approval Notice for the Supplemental Drug Application of Amino Acid (15) Peritoneal Dialysis Solution
August 1, 2025
Announcement on the FDA Approval for Clinical Trial of DC50292A Tablets by Wholly-owned Sub-subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.
July 29, 2025